BMO Capital Markets restated their outperform rating on shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) in a research note released on Wednesday morning. They currently have a $173.00 price objective on the biopharmaceutical company’s stock, up from their prior price objective of $168.00.
Several other analysts also recently issued reports on the company. J P Morgan Chase & Co upgraded Alexion Pharmaceuticals from a neutral rating to an overweight rating and boosted their price objective for the stock from $163.00 to $175.00 in a report on Tuesday, September 5th. BidaskClub upgraded Alexion Pharmaceuticals from a buy rating to a strong-buy rating in a report on Sunday, August 20th. Evercore ISI assumed coverage on Alexion Pharmaceuticals in a report on Wednesday, August 16th. They set an in-line rating and a $137.00 price objective on the stock. Zacks Investment Research upgraded Alexion Pharmaceuticals from a hold rating to a strong-buy rating and set a $158.00 price objective on the stock in a report on Wednesday, August 2nd. Finally, Leerink Swann boosted their price objective on Alexion Pharmaceuticals from $136.00 to $170.00 and gave the stock an outperform rating in a report on Friday, July 28th. Five equities research analysts have rated the stock with a hold rating, twenty have assigned a buy rating and three have issued a strong buy rating to the company. The stock currently has a consensus rating of Buy and an average target price of $157.13.
Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) traded up 1.44% during midday trading on Wednesday, hitting $146.69. 3,713,613 shares of the stock were exchanged. The stock’s 50-day moving average price is $138.83 and its 200 day moving average price is $124.75. The stock has a market cap of $32.74 billion, a P/E ratio of 63.61 and a beta of 1.40. Alexion Pharmaceuticals has a one year low of $96.18 and a one year high of $149.34.
Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.08 by $0.48. The firm had revenue of $912.00 million for the quarter, compared to the consensus estimate of $846.15 million. Alexion Pharmaceuticals had a return on equity of 12.47% and a net margin of 15.31%. The business’s revenue for the quarter was up 21.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.13 EPS. On average, analysts anticipate that Alexion Pharmaceuticals will post $5.62 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This story was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another site, it was illegally copied and reposted in violation of United States and international trademark & copyright legislation. The original version of this story can be accessed at https://www.dispatchtribunal.com/2017/09/16/alexion-pharmaceuticals-inc-alxn-earns-outperform-rating-from-bmo-capital-markets.html.
In other news, EVP Julie O’neill sold 11,160 shares of the stock in a transaction that occurred on Monday, August 28th. The stock was sold at an average price of $140.00, for a total value of $1,562,400.00. Following the completion of the sale, the executive vice president now directly owns 26,704 shares of the company’s stock, valued at $3,738,560. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Ann M. Veneman sold 700 shares of the stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $137.74, for a total value of $96,418.00. Following the completion of the sale, the director now directly owns 6,315 shares of the company’s stock, valued at $869,828.10. The disclosure for this sale can be found here. Insiders sold 17,070 shares of company stock valued at $2,416,869 over the last three months. 4.35% of the stock is owned by company insiders.
A number of hedge funds have recently modified their holdings of the stock. Aldebaran Financial Inc. bought a new position in Alexion Pharmaceuticals in the second quarter worth $426,000. Toronto Dominion Bank lifted its position in Alexion Pharmaceuticals by 25.5% in the second quarter. Toronto Dominion Bank now owns 76,071 shares of the biopharmaceutical company’s stock worth $9,254,000 after purchasing an additional 15,464 shares during the period. WINTON GROUP Ltd bought a new position in Alexion Pharmaceuticals in the second quarter worth $296,000. Public Employees Retirement System of Ohio lifted its position in Alexion Pharmaceuticals by 1.6% in the second quarter. Public Employees Retirement System of Ohio now owns 151,163 shares of the biopharmaceutical company’s stock worth $18,392,000 after purchasing an additional 2,394 shares during the period. Finally, Wealthsource Partners LLC lifted its position in Alexion Pharmaceuticals by 4.4% in the second quarter. Wealthsource Partners LLC now owns 3,002 shares of the biopharmaceutical company’s stock worth $365,000 after purchasing an additional 126 shares during the period. 94.26% of the stock is owned by hedge funds and other institutional investors.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.